Do you want to read an article? Please log in or register.
Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration
Genitourinary Cancer
COMMENTED
Related content
Genitourinary Cancer
Olaparib for Metastatic Castration-Resistant Prostate Cancer
N Engl J Med.
de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Sartor O, Agarwal N, Olmos D, Thiery-Vuillemin A, Twardowski P, Mehra N, Goessl C, Kang J, Burgents J, Wu W, Kohlmann A, Adelman CA, Hussain M
doi: 10.1056/NEJMoa1911440.
Genitourinary Cancer
Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer
Eur Urol.
Chen WS, Aggarwal R, Zhang L, Zhao SG, Thomas GV, Beer TM, Quigley DA, Foye A, Playdle D, Huang J, Lloyd P, Lu E, Sun D, Guan X, Rettig M, Gleave M, Evans CP, Youngren J, True L, Lara P, Kothari V, Xia Z, Chi KN, Reiter RE, Maher CA, Feng FY, Small EJ, Alumkal JJ, West Coast Prostate Cancer Dream Team
doi: 10.1016/j.eururo.
Genitourinary Cancer
Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial
Eur Urol.
Armstrong AJ, Lin P, Tombal B, Saad F, Higano CS, Joshua AM, Parli T, Rosbrook B, van Os S, Beer TM
doi: 10.1016/j.eururo.2020.04.061.
Genitourinary Cancer
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial
doi: 10.1016/S1470-2045(19)30684-9.
Genitourinary Cancer
Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer
Eur J Cancer.
van der Doelen MJ, Isaacsson Velho P, Slootbeek PHJ, Pamidimarri Naga S, Bormann M, van Helvert S, Kroeze LI, van Oort IM, Gerritsen WR, Antonarakis ES, Mehra N
doi: 10.1016/j.ejca.2020.05.001.
COMMENTED
Genitourinary Cancer
Optimizing the management of castration-resistant prostate cancer patients: A practical guide for clinicians
★ 1
Recommended and commented by
Prof. Dr Richard Cathomas, Faculty Member
Prostate.
Shore ND, Drake CG, Lin DW, Ryan CJ, Stratton KL, Dunshee C, Karsh LI, Kaul S, Kernen K, Pieczonka C, Sieber P, Stewart C, Williams M, Concepcion RS
doi: 10.1002/pros.24053.
Genitourinary Cancer
Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate cancer: a biomarker analysis of a multi-center international trial
Ann Oncol
Jayaram A, Wingate A, Wetterskog D, Wheeler G, Sternberg CN, Jones R, Berruti A, Lefresne F, Lahaye M, Thomas S, Gormley M, Meacham F, Garg K, Lim LP, Merseburger AS, Tombal B, Ricci D, Attard G
doi: 10.1016/j.annonc.2021.03.196
Genitourinary Cancer
HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studies
Ann Oncol.
Khalaf DJ, Aragón IM, Annala M, Lozano R, Taavitsainen S, Lorente D, Finch DL, Romero-Laorden N, Vergidis J, Cendón Y, Oja C, Pacheco MI, Zulfiqar M, PROREPAIR-B investigators., Gleave ME, Wyatt AW, Olmos D, Chi KN, Castro E
doi: 10.1016/j.annonc.2020.06.006.
Genitourinary Cancer
Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer
N Engl J Med.
Hussain M, Fizazi K, Saad F, Rathenborg P, Shore N, Ferreira U, Ivashchenko P, Demirhan E, Modelska K, Phung, Krivoshik A, Sternberg CN
doi: 10.1056/NEJMoa1800536.